Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
Small Molecule Pharmaceutical Sciences, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Int J Pharm. 2023 Apr 25;637:122874. doi: 10.1016/j.ijpharm.2023.122874. Epub 2023 Mar 21.
Lipid nanoparticles (LNPs) have been widely investigated for nucleic acid therapeutic delivery, and demonstrated their potential in enabling new mRNA vaccines. LNPs are usually formulated with multi-lipid components and the composition variables may impact their structural properties. Here, we investigated the impact of helper lipids on physicochemical properties of LNPs using a Design of Experiments (DoE) definitive screening design. Phospholipid head group, degree of unsaturation, ratio to cholesterol as well as PEG-lipid content were varied and a series of 14 LNPs were prepared by microfluidic- and solvent-injection mixing. Solvent-injection mixing by a robotic liquid handler yielded 50-225 nm nanoparticles with highly ordered, ∼5 nm inter-lamellar spacing as measured by small angle X-ray scattering (SAXS) and confirmed by cryo-transmission electron microscopy (cryo-EM). In contrast, microfluidic mixing resulted in less ordered, notably smaller (50-75 nm) and more homogenous nanoparticles. Significant impacts of the stealth-lipid DSPE-PEG2000 on nanoparticle size, polydispersity and encapsulation efficiency of an oligonucleotide cargo were observed in LNPs produced by both methods, while varying the phospholipid type and content had only marginal effect on these physicochemical properties. These findings suggest that from a physicochemical perspective, the design space for combinations of helper lipids in LNPs may be considerably larger than anticipated based on the conservative formulation composition of the currently FDA-approved LNPs, thereby opening opportunities for screening and optimization of novel LNP formulations.
脂质纳米粒 (LNPs) 已广泛应用于核酸治疗药物的递送,并在新型 mRNA 疫苗的应用中显示出其潜力。LNPs 通常由多种脂质成分组成,而成分的变化可能会影响其结构特性。在这里,我们使用实验设计(DoE)确定性筛选设计来研究辅助脂质对 LNPs 理化性质的影响。改变了磷脂头部基团、不饱和程度、与胆固醇的比例以及 PEG 脂质含量,并通过微流控和溶剂注入混合制备了一系列 14 种 LNPs。通过机器人液体处理机进行溶剂注入混合,得到了 50-225nm 的纳米颗粒,小角 X 射线散射(SAXS)测量和冷冻传输电子显微镜(cryo-EM)证实其具有高度有序的、约 5nm 的层间间距。相比之下,微流控混合得到的纳米颗粒则不太有序,粒径明显更小(50-75nm)且更均匀。通过这两种方法制备的 LNPs 中,隐形脂质 DSPE-PEG2000 对寡核苷酸货物的纳米颗粒大小、多分散性和包封效率有显著影响,而改变磷脂类型和含量对这些理化性质只有微小影响。这些发现表明,从理化角度来看,LNPs 中辅助脂质组合的设计空间可能比目前 FDA 批准的 LNPs 的保守配方组成所预期的要大得多,从而为新型 LNP 配方的筛选和优化提供了机会。